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Abstract Metabolic stability, mutagenicity, antimutagenicity, and the ability to scavenge
free radicals of four novel 8-methoxy-purine-2,6-dione derivatives (compounds 1–4)
demonstrating analgesic and anti-inflammatory properties were determined. Metabolic
stability was evaluated in Cunninghamella and microsomal models, mutagenic and
antimutagenic properties were assessed using the Ames and the Vibrio harveyi tests,
and free radical scavenging activity was evaluated with 2,2-diphenyl-1-picrylhydrazyl
radical scavenging assay. In the Cunninghamella model, compound 2 did not undergo
any biotransformation; whereas 3 and 4 showed less metabolic stability: 1–9 and 53–
88% of the parental compound, respectively, underwent biotransformation reactions in
different Cunninghamella strains. The metabolites detected after the biotransformation of
3 and 4 were aromatic hydroxylation and N-dealkylation products. On the other hand, the
N-dealkylation product was the only metabolite formed in microsome assay. Addition-
ally, these derivatives do not possess mutagenic potential in microbiological models
(Vibrio harveyi and Salmonella typhimurium) considered. Moreover, all compounds
showed a strong chemopreventive activity in the modified Vibrio harveyi strains BB7X
and BB7M. However, radical scavenging activity was not the mechanism which ex-
plained the observed chemopreventive activity.
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Introduction
During the biotransformation processes, drugs and chemicals are structurally modified by
various enzymatic systems to form more polar substances, which can be excreted more easily
than the original compounds. Problems arise when these modifications generate toxic products
[1, 2]. Traditionally, drug metabolism studies use in vivo experiments in mice, rat or guinea
pig, or chimeric mouse models with transplanted human hepatocytes [3, 4]. However, these
models can create ethical dilemmas; and the experiments are expensive and time consuming
[3]. In addition, metabolites are sometimes produced in low amounts, thus hindering their
identification [4].
Enzymatic systems involved in the metabolism of exogenous organic compounds are
similar in mammals and in certain fungal microorganisms, like Cunninghamella. Therefore,
Cunninghamella fungi can be used as an alternative to in vivo metabolism models [1–3, 5–8].
The use of these microorganisms enables the reduction of research costs and does not arise
ethical dilemmas. These alternative tests are simple and reliable as metabolites can be easily
extracted to be identified later using instrumental analytical techniques [3]. Cunninghamella
echinulata contains a rich set of microsomal cytochrome P450, and it can conduct phase I
(oxidative) and phase II (conjugative) biotransformation under certain conditions. Moreover,
the fungus possesses the ability to metabolize a wide variety of xenobiotics in regio- and
stereo-selective manners [9].
A second alternative to in vivo metabolism assays of chemical compounds are in vitro
screening assays with liver microsomes: they can predict the metabolic routes of tested
compounds, as well as kinetics of these transformations [10]. Cytochrome P450 enzymes
are involved in phase I reactions, whereas phase II reactions are commonly carried out by
different transferase enzymes such as glutathione transferase and N-acetyltransferase [11]. As
microsomal assays have a good reproducibility and performing them is straightforward, they
are becoming a standard in vitro screening in drug discovery processes [12–14]. Finally, liver
microsomes from different species (such as rat, mouse, dog, monkey, and human) can be used
to provide more accurate data [11].
Zygmunt et al. [15, 16] reported in previous studies that some novel derivatives of 8-
methoxy-purine-2,6-diones substituted at 7-position of purine core by carboxylic, ester, or
amide moieties showed potent anti-inflammatory and analgesic activity, superior to the
reference drug, in preliminary pharmacological studies [15, 16]. Their analgesic properties
were evaluated in two pharmacological in vivo models: formalin and writhing syndrome tests.
On the other hand, anti-inflammatory potential of the aforesaid compounds was determined
using zymosan-induced peritonitis and carrageenan-induced edema models. Derivatives con-
taining an amide substituent showed very strong analgesic and anti-inflammatory
(antiedematous) activities. The most active compound (4) showed a 23-fold and a 36-fold
higher activity than acetylsalicylic acid (the analgesic used in clinical practice considered as
reference) in the writhing syndrome test in mice and in the formalin test in mice, respectively
[15, 16]. Thus, these newly synthesized derivatives represent a new class of analgesic and anti-
inflammatory agents with possible future therapeutic applications in the treatment of inflam-
matory diseases and in the attenuation of pain. However, once verified their promising activity,
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more in-depth studies need to be performed in their pharmacology, pharmacokinetics, safety,
and toxicology, among other fields, to evaluate the feasibility of the possible clinical applica-
tions of these compounds, as well as to know better how they exert their action.
In line to this, the aim of this study was to investigate in vitro biotransformation and some
biological activities of the four (1–4) most promising 8-methoxy-purine-2,6-dione derivatives
(Fig. 1) selected on the basis of their activity [15, 16]. The activities evaluated in the present
study are mutagenicity, antimutagenicity, metabolic biotransformations, and the ability of the
compounds to scavenge free radicals. Among the four compounds tested, there are 2-(8-
methoxy-1,3-dimethyl-2,6-dioxo-purin-7-yl)acetic acid (1), methyl 2-(8-methoxy-1,3-dimeth-
yl-2,6-dioxo-purin-7-yl)acetate (2), N-benzyl-4-(8-methoxy-1,3-dimethyl-2,6-dioxo-purin-7-
yl)butanamide (3), and 8-methoxy-1,3-dimethyl-7-[4-oxo-4-(4-phenylpiperazin-1-
yl)butyl]purine-2,6-dione (4).
Materials and Methods
Tested Compounds
Four 8-methoxy-purine-2,6-dione derivatives (1–4) described in previous publications [15, 16]
were provided by Dr. Grażyna Chłoń-Rzepa from the Department of Medicinal Chemistry,
Jagiellonian University Medical College. The structures of these compounds were established
on the basis of CHN elemental analysis and spectral data (IR, 1HNMR, and mass spectra).
Additionally, qualitative analysis was performed using TLC and HPLC.
In the Cunninghamella biotransformation assay, 12.5 mg of compounds 2–4 were dissolved
in 0.5 mL of DMSO to be later inoculated in 24.5 mL of broth medium containing fungus,
being thus 0.5 mg/mL the final concentration. For rat microsomal assay, 5.1 mM stock
solutions of compounds 1 and 3 were prepared in water and ethanol, respectively. From them,
0.2 mM working solutions were prepared by dilution with water. In mutagenic tests, com-
pounds 1–4 were dissolved in pure DMSO to obtain the corresponding stock solution (10 mg/
mL). Working solutions were prepared by 1:100 dilution of stock solution in water, and final
compound concentration assayed was 40 ng/mL. Finally, for 2,2-diphenyl-1-picrylhydrazyl
(DPPH) assay, 1 mM stock solutions of compounds 1–4 were prepared in methanol.
Fig. 1 Chemical structures of compounds 1–4
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Reagents
4-Nitroquinoline N-oxide (NQNO), DMSO, L-histidine monochloride, yeast extract,
levallorphan, NADP+, glucose-6-phosphate sodium salt, glucose-6-phosphate dehydrogenase,
potassium hydroxide, DPPH, gallic acid, and ascorbic acid were purchased from Sigma-
Aldrich (Seelze, Germany); Nutrient Broth No. 2, from Argenta (Poznań, Poland); glycerol
and neomycin sulfate, from Pharma Cosmetic (Kraków, Poland); sodium sulfate, sodium
chloride, D-glucose, and dipotassium hydrogen phosphate from Chempur (Piekary Śląskie,
Poland); dichloromethane from Stanlab (Lublin, Poland); and agar-agar, bacto-peptone, beef
extract, potato dextrose agar, and 0.2-mm silica-coated aluminum TLC plates from Merck
(Darmstadt, Germany).
Cunninghamella Strains and Culture Conditions
Three different strains of Cunninghamella were used: Cunninghamella echinulata NRRL
1384, Cunninghamella blakesleeana 1908 DMS, and Cunninghamella elegans 1906 DMS.
The first was provided by Dr. A.J. Carnell (University of Liverpool, UK), whereas the two
remaining were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH (DMSZ, Braunschweig, Germany).
Cunninghamella strains were cultivated on solid potato dextrose agar (PDA) plates at
28 °C. After 4 days, a liquid fermentation basal medium was prepared by the addition of
6 g of D-glucose, 1.5 g of NaCl, 1.5 g of yeast extract from Saccharomyces cerevisiae, and
1.5 g of K2HPO4 to 300 mL of distilled water. Aliquots of 24.5 mL of medium were inoculated
with 300 μL of suspension of fungal spores obtained after wetting colonies in PDA. The fungi
were incubated with shaking until the formation of spherical clumps.
Cunninghamella Biotransformation Assay
Compounds 2–4 were evaluated in this experiment. Once microorganisms formed spherical
clumps in the preliminary incubation, the corresponding tested compound was added to the
broth and the mixture was incubated for 7 days. Two control experiments were also performed,
in the absence of compound and fungus, respectively [3, 9]. Biotransformation progress was
monitored by TLC and by liquid chromatography electrospray ionization-tandem mass spec-
trometry (LC-MS/MS). Monitoring was performed at four different incubation times: 30 min,
3 days, 5 days, and 7 days.
To analyze metabolites in LC-MS/MS, an aliquot of 500 μL of filtered sample was taken
and extracted with 500 μL of dichloromethane. The organic fraction was dried with sodium
sulfate, filtered, and evaporated. The obtained residue was analyzed in LC-MS/MS. At the end
of experiment, all the remaining medium was extracted with 25 mL of dichloromethane after
separating the fungal clumps by filtration over cellulose filters [3, 17].
Microsomal Stability Assay
Compounds 1 and 3 were studied in a biotransformation assay using rat liver microsomes
following procedures described previously [18–22]. The reagents used in this assay were
levallorphan (internal standard) and NADPH-regenerating system, which contained phosphate
buffer (pH 7.4), NADP+, glucose-6-phosphate, and glucose-6-phosphate dehydrogenase [18].
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The final protein concentration in the assay was 0.4 mg/mL. Compounds 1 and 3 were tested at
a final concentration of 20 μM.
The amount of a parental compound remaining in a solution after biotransformation was
monitored using LC-MS/MS as described previously in BCunninghamella Biotransformation
Assay.^ Graphs representing ln of percentage of parent compound remaining versus incuba-
tion time were drawn to calculate in vitro half-time (t1/2) from the slope of linear regression. To
obtain intrinsic clearance (Clint) of a tested compound in rat liver microsomal assay, t1/2
previously calculated was substituted at the equation Clint = [(Vmic/Pmic) × 0.693/t1/2], being
Vmic and Pmic the volume of incubation in microliters and the amount of incubated protein in
milligrams, respectively [23, 24].
Analytical Methods
TLC experiments were performed using 0.2-mm silica-coated aluminum plates, being a 95:5
dichloromethane/methanol mixture the mobile phase. The plates were observed under UV
light.
Agilent 1100 HPLC system (Agilent Technologies, Waldbronn, Germany) equipped
with a Xbridge™ C18 analytical column (2.1 × 30 mm, 3.5 μM; Waters, Dublin, Ireland)
was used in the chromatographic separation of LC-MS/MS analysis. An elution gradient
of acetonitrile and water, with 0.1% of formic acid, was used as a mobile phase. MS
spectra were taken at Applied Biosystems MDS Sciex API 200 triple quadrupole mass
analyzer (Concord, Ontario, Canada) with an electrospray ionization (ESI) interface
between HPLC and MS.
Bacterial Strains
Four Vibrio harveyi strains were used in this study: a wild-type BB7 (naturally found in the
Baltic Sea) and three genetically modified strains, namely BB7M (obtained by the introduction
of pAB1273 plasmid containing the genes mucA and mucB to enhance the error-prone DNA
repair), BB7X (hypersensitive to UV radiation after genetic modification with Tn5TpMCS),
and BB7XM (containing the two abovementioned modifications) [25–28]. These strains were
kindly provided by Prof. G. Węgrzyn (Department of Molecular Biology, University of
Gdańsk, Poland).
In the Ames test, Salmonella typhimurium TA100 strain was used. This strain has a
base-pair substitution that can be reverted by mutations at GC pairs. In addition, it
contains mutations at uvrB-bio and rfa genes to eliminate excision repair mechanisms
and to make the bacteria more permeable to chemicals, respectively. Finally, TA100 also
includes pKM101 plasmid, which enhances both chemical and UV-induced mutagenesis
via an increase in the error-prone recombinational DNA repair pathway [29, 30]. TA100
strain of S. typhimurium was provided by Dr. T. Nohmi (Division of Genetics and
Mutagenesis, National Institute of Hygienic Sciences, Tokyo, Japan). V. harveyi and
S. typhimurium bacterial cultures were maintained at 30 and 37 °C, respectively.
Mutagenic Agent
A standard mutagen NQNO was used as a positive control in mutagenicity assays and as a
mutagen added to all probes (except negative controls) in antimutagenicity tests. It causes
128 Appl Biochem Biotechnol (2018) 184:124–139
point mutations at the genome as it induces G:C → A:T transitions in Vibrio harveyi strains
[27, 31] and in other bacteria such as Escherichia coli and S. typhimurium [32]. NQNO was
initially dissolved in DMSO. Next, its working solution was prepared in sterile water, being
40 ng/mL its final concentration.
Vibrio harveyi and Ames Mutagenicity Assays
To perform the V. harveyi mutagenicity test, 10 μL of a working solution of the tested
compound (100 μg/mL) were added to V. harveyi bacterial culture (OD600 = 0.1) in
NaCl-containing BOSS liquid medium, being 40 ng/mL the final concentration of the
tested compound. The samples were left incubating till OD600 increased to 0.3–0.4.
Then, an inoculum containing 5 × 106 cells was added to solid BOSS agar plate
supplemented with neomycin sulfate at a final concentration of 100 μg/mL. Samples
were left incubating 48 h at 30 °C, and revertant colonies were counted manually. A
positive control with NQNO and two negative controls (DMSO and blank water probe)
were also tested. Each experiment was performed in triplicate, and results were given in
terms of mutagenic index (MI), which is the quotient between the number of revertant
colonies induced in a test sample and the number of revertants in a negative control
[33–35]. A compound is considered mutagenic if MI is above 2.0 or if the number of
revertants is higher in compound samples that in NQNO ones [26, 31].
Additionally, two different final concentrations of compounds (40 and 500 ng/mL)
were evaluated in the Ames test to confirm the results obtained in the Vibrio harveyi
assay using a second independent method. Positive (NQNO, concentration of 40 ng/mL)
and negative (DMSO) controls were also tested. S. typhimurium was cultivated in a fresh
medium 12 h prior to a test. To perform mutagenicity assay, 100 μL of an overnight
culture (containing approx. 1 × 108 to 2 × 108 bacteria) were inoculated along with
50 μL of a tested compound in 2 mL of top agar supplemented with traces of histidine
and of biotin. Then the mixture was added over the surface of GM agar plates and was
left incubating 48 h at 37 °C. Afterwards, the colonies were counted manually [25, 28].
A compound is considered mutagenic if MI >2.0 or if compound samples contain more
revertants than NQNO controls [33–36].
Vibrio harveyi Antimutagenicity Assay
Procedure followed in the V. harveyi antimutagenicity assay [34, 35] was similar to the
mutagenicity method described before. Differential point is that 10 μL of NQNO (final
concentration of 40 ng/mL) were added to V. harveyi bacterial culture in BOSS liquid
medium 15 min after the addition of tested compound to the culture. The results were
expressed as the inhibition percentage of mutagenic effect, which was calculated with the
formula: 100 − [(R1/R2) × 100], where R1 is the number of revertants per plate in the
presence of both mutagen and tested substance, and R2 is the number of revertants per
plate in the presence of mutagen [34, 36]. The antimutagenic effect was considered
weak/absent, moderate, or strong when the inhibition percentage was up to 25%, from 25
to 40%, and higher than 40%, respectively [34, 37]. S. typhimurium antimutagenicity
assay was based on similar assumptions as the V. harveyi antimutagenicity test. In this
case, the chemopreventive activity was determined at two concentrations of a tested
compounds and a standard mutagen, i.e., 40 and 500 ng/mL.
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DPPH Assay
The capacity of selected 8-methoxy-purine-2,6-dione derivatives to scavenge stable free
radical DPPH was assessed [22, 38–42]. A blank and a triplicate of 10 different concentrations
of each compound or of each positive control (gallic and ascorbic acids) were evaluated in the
experiment. Aforesaid concentrations of compounds were obtained by dilution from a
1000 μM stock solution in methanol. One hundred microliters of DPPH stock solution were
added to each well; later, 100 μL of the corresponding compound dilution were added.
Consequently, the final concentration of DPPH radical was 250 μM, whereas the final
concentrations of the tested compounds or positive controls were 500, 375, 250, 125, 62.5,
50, 37.5, 25, 12.5, and 6.25 μM. Afterwards, the 96-plate was wrapped with aluminum and
stored in the dark 30 min prior to the spectrophotometric measurement at a 517-nm wave-
length. The obtained absorbances were used to calculate the percentage of radical scavenged
by the action of a compound or of a positive control at each concentration using a formula
100 × (A0 − Am)/A0. In this equation Am is the average absorbance of the three triplicates
measured at the corresponding concentration and A0 is the average absorbance of DPPH
radical in the absence of the tested substance. Knowing inhibition data at the different
concentrations, IC50 was calculated when applicable [40].
Results
Cunninghamella Biotransformation
The metabolic degradation of compounds 2–4 was studied in the Cunninghamella biotrans-
formation assay, being these derivatives tested in three different Cunninghamella species:
C. echinulata, C. blakesleeana, and C. elegans. Compound 1 was not evaluated within this
experiment due to its structural similarity to compound 2. Metabolites were determined
through the study of the corresponding LC-MS/MS spectra. Unless stated otherwise, the
metabolites discussed onwards are the ones found at the end of experiment after 7-day
incubation of investigated purine-2-6-dione derivatives with the corresponding
Cunninghamella strain.
None of the three Cunninghamella strains evaluated generated detectable metabolites of 2
in a biotransformation assay, according to the LC-MS/MS spectra recorded. The main peak
observed in LC-MS/MS corresponded with protonated molecule [M + H]+ of 2 (m/z 283) and
was eluted in LC at a retention time of 3.52 min.
In case of 3, a protonated molecule [M + H]+ (m/z 386) of a parental compound (Fig. 2)
remained to be the most important derivative ion present in the extract, as only a 0.6, 4.6, and
7.6% of a tested compound was metabolized at the end of experiment in C. elegans,
C. blakesleeana, and C. echinulata, respectively (Table 1). The main metabolite (3-M4) in
three strains corresponded to the product of aromatic hydroxylation (Fig. 3) of a parental
compound, and was eluted at a retention time of 3.62 min (m/z 402). The percentages of the
metabolite observed were 0.6, 4.6, and 4.2% in C. elegans, C. blakesleeana, and C. echinulata,
respectively. No more metabolites were detected in the first two strains. C. echinulata gener-
ated three additional metabolites in the biotransformation assay. The first of these three
metabolites (3-M1) had a retention time of 2.75 min, an abundance of 1.5%, and an m/z of
296. On the other hand, the main peak in MS of the two remaining metabolites had a molecular
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weight of 402 (Fig. 3). The percentages of appearance of these two metabolites and their
retention times were 3.79 min and 0.3% for the first metabolite (3-M3) and 4.29 min and 1.6%
for the second (3-M2) (Table 1, Figs. 3 and 4).
A protonated molecule [M + H] at m/z 441 was detected in mass spectra of four after the
biotransformation processes, corresponding to a molecular weight (m/z 440) of a parental
compound. In all Cunninghamella strains, only one metabolite (4-M1), the product of aromatic
hydroxylation, was observed, at a retention time of 3.37 min and with m/z 457. The calculated
percentages of the parental compound metabolized in each case were 53.0, 66.6, and 87.6% in
C. elegans, C. blakesleeana, and C. echinulata, respectively (Table 1, Fig. 4).
Microsomal Biotransformation
The metabolic stability of compounds 1 and 3 was measured by the incubation with rat liver
microsomes and subsequent monitoring of the metabolites formed by LC-MS/MS. Compound
2 was not examined with microsomes due to its metabolic stability in a former
Cunninghamella assay. During the microsomal biotransformation, compound 1 was metabol-
ically stable as no metabolites were observed after 1 h of its incubation with microsomes: only
a protonated paternal compound was detected in LC-MS/MS spectra.
On the other hand, only one metabolite (3-M1) of compound 3 (Table 2) was observed after
rat microsomal incubation, being its molecular weight and its retention time 296 g/mol and
2.78 min, respectively. The metabolite found was the product of the N-dealkylation of a
Fig. 2 LC-MS/MS spectra compound 3 and its 3-M1 metabolite
Table 1 Metabolites of compounds 3 and 4 detected in Cunninghamella biotransformation assay
Metabolite/compound % of compound/metabolite in blank or different
Cunninghamella strains
Cmp. tr
(min)
[M +
H]+
Biotransformation reaction
type
Blank C. elegans C. blakesleeana C. echinulata
3 4.61 386 Parental compound 100.0 99.4 95.4 92.4
3-M1
3-M2
3-M3
3-M4
2.75
4.29
3.79
3.62
296
402
402
402
N-dealkylation
Aromatic hydroxylation
Aromatic hydroxylation
Aromatic hydroxylation
–
–
–
–
–
–
–
0.6
–
–
–
4.6
1.5
1.6
0.3
4.2
4 5.19 441 Parental compound 100.0 47.0 33.3 12.4
4-M1 3.37 457 Aromatic hydroxylation – 53.0 66.6 87.6
tr retention time
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parental compound (Fig. 4). Calculated in vitro half-time (t1/2) for 3 was 17.7 min, and intrinsic
clearance (Clint) was 97.88 μL/min/mg protein (Fig. 5).
Mutagenicity
The results of mutagenicity assay in four Vibrio harveyi strains are shown in Table 3. None of
the evaluated four 8-methoxy-purine-2,6-dione derivatives displayed mutagenicity at the
concentration of 40 ng/mL, as MI of four investigated compounds was always below 2.0 in
Fig. 3 LC-MS/MS spectra of compound 3 and its metabolites 3-M2, 3-M3, and 3-M4
Fig. 4 General scheme for compounds 3 and 4 biotransformation pathways in Cunninghamella and microsomal
models
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all the Vibrio harveyi strains analyzed and the number of revertants counted in test samples
was always lower than the values determined for NQNO controls. Moreover, all investigated
compounds were also devoid of mutagenic activity according to the Ames test performed at
the compound concentrations of 40 and 500 ng/mL (Table 3) using the Salmonella
typhimurium TA100 strain.
Antimutagenicity
According to data obtained in the antimutagenicity assay (Table 4), four 8-methoxy-purine-
2,6-dione derivatives inhibited the mutagenic action of a standard mutagen NQNO in four
Vibrio harveyi strains evaluated. All derivatives exhibited a very strong chemopreventive
activity in two modified V. harveyi strains (BB7X and BB7M). The antimutagenic percentages
calculated ranged from 56 to 74%, and from 39 to 54% in BB7X and BB7M strains,
respectively. In contrast, 1 (20%), 2 (38%), and 3 (29%) exerted a moderate or a close to
moderate chemopreventive effect in a wild BB7 strain, whereas 4 (53%) was a strong
chemopreventive agent in the same strain. Finally, chemopreventive activity exerted by the
evaluated 8-methoxy-purine-2,6-dione derivatives was much lower in the BB7XM strain, in
which chemopreventive percentages ranged from 9 to 15%. Moreover, all derivatives showed
a very potent antimutagenic activity in S. typhimurium TA100 strain. The chemopreventive
percentages ranged from 88 to 96% and from 88 to 95% for concentrations of 40 and of
500 ng/mL, respectively (Table 4).
Table 2 Metabolites of compound 3 observed in rat microsomal biotransformation after 30 min of incubation
Cmp. tr (min) [M + H]
+ Biotransformation reaction type % content among metabolites
3 4.61 386 Parental compound −
3-M1 2.75 296 N-dealkylation 100
tr retention time
Fig. 5 Graphical calculation of t1/2 during biotransformation in rat liver microsomes of compound 3 and its
depletion along time
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Antioxidant Activity
None of the compounds 1–4 showed capacity to scavenge DPPH radical, in comparison to
positive controls considered (ascorbic and gallic acids). The maximum radical scavenging
percentage observed was 6.56% for 3 at the concentration of 250 μM.
Discussion
Within the present study, in vitro biotransformation of some promising 8-methoxy-purine-2,6-
dione derivatives (1–4) was investigated. Additionally, muta-, antimutagenicity, and antioxi-
dant potency of investigated compounds were assessed.
Among the tested compounds, 1 and 2 were metabolically stable as 1 did not undergo
biotransformation in rat microsomes and no metabolites of 2 were detected in the
Cunninghamella model. Cunninghamella biotransformation of compounds 3 and 4 rendered
as metabolites the product of aromatic hydroxylation in both compounds and N-dealkylation
metabolite of compound 3. Nevertheless, this last metabolite was only detected in 3 with
C. echinulata. With reference to M2 and M3 metabolites of 3, we have three possible different
aromatic hydroxylation isomers: ortho-, meta- and para-hydroxylated metabolites. From a
chemical point of view, −CH2-NH-R substituent present in 4 is a mild electron donating
moiety which activates slightly benzene ring in electrophilic aromatic substitution. In this
reaction, the added hydroxyl group is directed preferably towards para- and ortho-positions,
being meta-position the least favored. Furthermore, the steric hindrance plays an important
role, promoting para- direction over ortho-direction. Therefore, considering the percentages of
metabolites and their polarity (in reverse order than retention time, and supposing that para-
will be slightly more polar than meta-, and meta- than ortho-), we hypothesize that the
biotransformation products at retention times of 3.62, 3.79, and 4.29 min are the products of
para-hydroxylation (3-M4), meta-hydroxylation (3-M3), and ortho-hydroxylation (3-M2)
reactions of 3, respectively. This hypothesis also explains why para-hydroxylated metabolite
(3-M4) is the only one observed after the biotransformation of 3 in C. elegans and in
C. blakesleeana. Regarding compound 4, by analogy with 3, we hypothesize that the product
of its aromatic hydroxylation is para-hydroxylated derivative.
On the other hand, N-dealkylation product (3-M1) was a unique metabolite observed in
microsomal biotransformation of 3, being its intrinsic clearance quite high. Consequently, 8-
methoxy-purine-2,6-dione ring is the most stable part of the molecule as it does not undergo
biotransformations, which are limited to 7-alkyl substituent of purine core. Probably, com-
pounds 1 and 2 do not suffer any biotransformation because they do not contain any aromatic
ring or secondary amides like derivatives 3 and 4.
Calculated in vitro half-time for 3 was 17.7 min, and intrinsic clearance was 97.88 μL/min/
mg protein. This Clint is high as it is 3.09-fold lower than the 302.00 μL/min/mg established
for imipramine [23]. This experimental fact means that 3 is metabolized relatively fast.
Four 8-methoxy-purine-2,6-dione derivatives evaluated in this study are safe from a mutagenic
point of view, as they successfully overcome two initial screenings of their mutagenic potential (the
Vibrio harveyi and the Ames tests) without displaying mutagenic activity. Interestingly, all the
investigated compounds showed antimutagenic potential, which means that they have chemopre-
ventive activity. Therefore, theymight potentially delay, inhibit, or even reverse carcinogenesis [38].
Nevertheless, the mechanism that explains their chemopreventive action is not the free radical
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scavenging activity, as they showed a low or non-existent capacity to quench DPPH radical in
DPPH assay performed. Thus, further research should be performed in the future to ascertain the
exact mechanism responsible for this chemopreventive activity [43, 44].
To sum up, within the study, metabolic profile and selected biological properties of some
novel 8-methoxy-purine-2,6-dione derivatives (compounds 1–4) with analgesic and anti-
inflammatory properties were evaluated. It was demonstrated that in the Cunninghamella
model, compound 2 did not undergo any biotransformation; whereas 3 and 4 showed less
metabolic stability as they underwent biotransformation reactions. Moreover, the new deriv-
atives of purine-2,6-dione do not possess mutagenic potential in the microbiological models
considered and showed a strong chemopreventive activity in the modified Vibrio harveyi
strains BB7X and BB7M.
Therefore, the obtained results might represent an important step in designing and planning
future studies with purinediones.
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